An interventional study of Immunotherapy CARE Program in Kidney Cancer, Bladder Cancer and Breast Cancer, sponsored by Memorial Sloan Kettering Cancer Center. Recruiting at 8 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.
Sponsored by Memorial Sloan Kettering Cancer Center · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 35 studies in Kidney Neoplasms by Memorial Sloan Kettering Cancer Center — 4 open to participants now, 9 under way, none of them phase 3. Kidney Neoplasms · Memorial Sloan Kettering Cancer Center.
Among the 35 studies in Kidney Neoplasms by Memorial Sloan Kettering Cancer Center, this one is the 4th largest by planned enrollment of the 21 interventional ones that give a count, is one of 2 that started in 2026, is one of 3 with no phase, and was the 34th registered.
969 studies on the registry are indexed under Kidney Neoplasms; 208 are open to participants now.
Browse Kidney Neoplasms studies →4 of the 35 studies in Kidney Neoplasms by Memorial Sloan Kettering Cancer Center are open now, in 1 country. Recruiting first, the newest first:
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+ · Healthy volunteers
Memorial Sloan Kettering Cancer Center · Sites in United States
Healthy volunteers
By country, each count listing its studies:
Of the 171 Kidney Neoplasms studies recruiting now, 131 (77%) set no upper age limit and 15 (9%) stop at 75 or younger; 20 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
35 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 18 · Phase 3 1 · Phase 4 1
First in 1990; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is above the median of 46 across 668 interventional studies indexed under Kidney Neoplasms.
Median enrollment 24 across the 21 interventional studies, 500 across the 3 observational. Of the 26 that completed or were terminated, 6 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
Memorial Sloan Kettering Cancer Center is the lead sponsor of 1,964 studies on the registry; 325 are open to participants now.
Of its 135 completed or terminated interventional studies of FDA-regulated products, 71 (53%) have results posted.
7 of the studies in Kidney Neoplasms by Memorial Sloan Kettering Cancer Center that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT00582621Memorial Sloan Kettering Cancer CenterAscertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders | 2026-12 |
| NCT02087852Memorial Sloan Kettering Cancer CenterKidney Cancer DNA Registry | 2027-03 |
| NCT00579514Memorial Sloan Kettering Cancer CenterGermline Alterations of Tumor Susceptibility Genes in New York Cancer Patients | 2027-03 |
| NCT05239533Memorial Sloan Kettering Cancer CenterStudy of Nivolumab in Combination With 177Lu-girentuximab for Kidney Cancer | 2027-03 |
| NCT01582204Memorial Sloan Kettering Cancer CenterEvaluate The Utility Of 124I-cG250 for The Early Detection Of Response to Therapy In Patients With Metastatic Renal Cell Carcinoma | 2027-04 |
Add all 7 to your calendar (.ics) → With an account.
Among the 35 studies in Kidney Neoplasms by Memorial Sloan Kettering Cancer Center, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to find out if the navigation program helps participants manage immunotherapy treatment better than usual care. Investigators will also look at how the navigation program impacts participants' quality of life. Investigators will measure quality of life by having participants complete questionnaires.
The criteria were revised on the registry on Oct 28, 2026. See what changed
Inclusion Criteria:
Documentation of Disease
o Patient must have confirmed kidney, bladder, breast, gastrointestinal or lung cancer (per EMR)
Prior Treatment
o Within three weeks (+/- 3 weeks) of starting or PD(L)-1 immune checkpoint inhibitors as monotherapy or in combination with other therapies (per EMR)
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunotherapy CARE Program
Other: Immunotherapy CARE Program
Enhanced Usual and Customary care and support (U\&C)
For participants assigned to the I CARE arm, CCNY staff will assist in monthly essential needs and side effects/symptom reporting navigation
Also known as: I CARE
Immune Checkpoint Inhibitors/ICI continuation
Participant ICI appointment and treatment adherence will be documented through chart abstraction (research staff EMR review) at 6 months
Time frame: 6 months
Plan to share: Yes — Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made following one year after publication and for up to 36 months later. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.
Started Jun 2026 (actual). Primary completion is estimated for Jun 2029, 36 months after the start.
Of 90 non-industry interventional studies with no phase under Kidney Neoplasms, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 94. This study's planned 36 months is below that.
Counting every sponsor, half of 97 studies reached it within 42 months; a quarter within 21 and three quarters within 90.
Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Jun 2026, on Oct 20, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Memorial Sloan Kettering Cancer Center →